Lundbeck gets EU marketing approval for Brintellix

Danish drugmaker Lundbeck has received marketing authorization from the European Commission for its antidepressant Brintellix following approval in the United States in September, it said on Friday. Brintellix is important for Lundbeck, which hopes it will provide a new source of revenue as its existing antidepressant Cipralex - sold as Lexapro in the United States and Japan - comes off patent. Cipralex is Lundbeck's single biggest source of revenue. The approval for Brintellix will cover all 28 European Union member states plus Iceland, Liechtenstein and Norway.



via Health News Headlines - Yahoo News http://news.yahoo.com/lundbeck-gets-eu-marketing-approval-brintellix-172556971--finance.html